EPS for Cellectis S.A. (CLLS) Expected At $-0.66; Stanley (SXE) Has 0.85 Sentiment

April 19, 2018 - By Maria Brooks

Cellectis S.A. (NASDAQ:CLLS) Logo

Analysts expect Cellectis S.A. (NASDAQ:CLLS) to report $-0.66 EPS on May, 8.They anticipate $0.10 EPS change or 17.86% from last quarter’s $-0.56 EPS. After having $-0.76 EPS previously, Cellectis S.A.’s analysts see -13.16% EPS growth. The stock decreased 2.20% or $0.68 during the last trading session, reaching $30.19. About 89,207 shares traded. Cellectis S.A. (NASDAQ:CLLS) has risen 30.21% since April 19, 2017 and is uptrending. It has outperformed by 18.66% the S&P500.

Stanley Inc (SXE) investors sentiment decreased to 0.85 in Q4 2017. It’s down -0.15, from 1 in 2017Q3. The ratio fall, as 11 funds started new and increased holdings, while 13 reduced and sold equity positions in Stanley Inc. The funds in our database reported: 2.17 million shares, up from 1.75 million shares in 2017Q3. Also, the number of funds holding Stanley Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 8 Increased: 5 New Position: 6.

Among 8 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Cellectis had 15 analyst reports since April 5, 2016 according to SRatingsIntel. The company was initiated on Tuesday, February 28 by Wells Fargo. Nomura maintained Cellectis S.A. (NASDAQ:CLLS) on Wednesday, September 6 with “Buy” rating. The firm has “Hold” rating given on Wednesday, September 6 by SunTrust. The firm has “Buy” rating by Jefferies given on Friday, October 27. On Friday, October 6 the stock rating was maintained by SunTrust with “Hold”. The stock of Cellectis S.A. (NASDAQ:CLLS) has “Buy” rating given on Thursday, August 24 by Jefferies. Ladenburg Thalmann initiated the shares of CLLS in report on Tuesday, April 5 with “Buy” rating. As per Wednesday, August 16, the company rating was maintained by Oppenheimer. The company was maintained on Friday, June 2 by Oppenheimer. As per Tuesday, June 6, the company rating was maintained by Jefferies.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.23 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

Southcross Energy Partners, L.P., together with its subsidiaries, provides natural gas gathering, processing, treating, compression, and transportation services in the United States. The company has market cap of $139.52 million. The firm also offers natural gas liquid fractionation and transportation services. It currently has negative earnings. In addition, it supplies natural gas to industrial, commercial, and power generation customers, as well as local distribution companies.

Analysts await Southcross Energy Partners, L.P. (NYSE:SXE) to report earnings on May, 8. They expect $-0.22 EPS, down 15.79% or $0.03 from last year’s $-0.19 per share. After $-0.21 actual EPS reported by Southcross Energy Partners, L.P. for the previous quarter, Wall Street now forecasts 4.76% negative EPS growth.

Hite Hedge Asset Management Llc holds 0.11% of its portfolio in Southcross Energy Partners, L.P. for 368,495 shares. Symphony Asset Management Llc owns 755 shares or 0.03% of their US portfolio. Moreover, Quinn Opportunity Partners Llc has 0.02% invested in the company for 66,246 shares. The Texas-based Center Coast Capital Advisors Lp has invested 0.01% in the stock. Freestone Capital Holdings Llc, a Washington-based fund reported 81,600 shares.

Southcross Energy Partners, L.P. (NYSE:SXE) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: